Pfizer's RSV vaccine, Abrysvo, generated $356 million in sales in Q3, down from $375 million last year, but the company reported a growing market share, exceeding 50% of shipped volume. Despite challenges from CDC guidelines affecting older adult uptake, maternal vaccination is seeing increased momentum. Pfizer is also advancing next-generation pneumococcal vaccines amid competition from Merck and Vaxcyte.
Pfizer's Hympavzi receives FDA approval for hemophilia treatment options
The FDA has approved Pfizer's Hympavzi for treating hemophilia A and B in patients aged 12 and older without inhibitors. This weekly injection reduces the activity of tissue factor pathway inhibitor, enhancing blood clotting. Hympavzi offers a new treatment option alongside gene therapies and other factor replacement drugs, showing superior results in lowering bleeding rates.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.